BeyondSpring - BYSI Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BYSI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BYSI, but not buy additional shares or sell existing shares.
View BYSI analyst ratings or view top-rated stocks.

6 analysts have issued twelve-month price objectives for BeyondSpring's stock. Their BYSI share price forecasts range from $5.00 to $65.00. On average, they expect the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,729.3% from the stock's current price.
View analysts price targets for BYSI or view top-rated stocks among Wall Street analysts.

BeyondSpring's stock was trading at $4.53 at the beginning of 2022. Since then, BYSI shares have decreased by 63.8% and is now trading at $1.64.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, September 9th 2022.
View our BYSI earnings forecast.

BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings results on Wednesday, December, 29th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.11. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.34 million. BeyondSpring had a negative net margin of 4,750.48% and a negative trailing twelve-month return on equity of 144.52%.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

BeyondSpring's stock is owned by many different retail and institutional investors. Top institutional investors include Millennium Management LLC (1.78%), Renaissance Technologies LLC (0.94%), BNP Paribas Arbitrage SA (0.64%), Hennion & Walsh Asset Management Inc. (0.24%), State Street Corp (0.24%) and Citadel Advisors LLC (0.00%).

Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BYSI stock can currently be purchased for approximately $1.64.

BeyondSpring (NASDAQ:BYSI) has a market capitalization of $63.85 million and generates $1.35 million in revenue each year. The company earns $-64,180,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The official website for the company is www.beyondspringpharma.com. The company can be reached via phone at (646) 305-6387, via email at general@beyondspringpharma.com, or via fax at 1-646-882-4228.